Source: https://app.leg.wa.gov/WAC/default.aspx?dispo=true&cite=246-887&full=true
Timestamp: 2020-01-26 21:35:16
Document Index: 223975092

Matched Legal Cases: ['§ 246', '§ 246', '§ 246', '§ 246', '§ 246', '§ 360', '§ 360', '§ 360', '§ 360', '§ 360', '§ 360', '§ 360', '§ 360', '§ 246', '§ 246', '§ 246', '§ 360', '§ 246', '§ 246', '§ 246', '§ 246', '§ 360', '§ 360', '§ 246', '§ 246', '§ 360', '§ 246', '§ 246', '§ 246', '§ 246', '§ 246', '§ 246', '§ 246', '§ 360', '§ 360', '§ 360', '§ 246', '§ 246', '§ 246', '§ 246', '§ 246', '§ 246', '§ 360', '§ 360', '§ 360', '§ 246', '§ 246', '§ 246', '§ 360', '§ 360', '§ 246', '§ 246', '§ 246', '§ 246', '§ 246', '§ 246', '§ 246', '§ 246', '§ 246', '§ 246', '§ 246', '§ 360', '§ 360', '§ 246', '§ 246', '§ 246', '§ 246', '§ 246', '§ 246', '§ 360', '§ 360', '§ 246', '§ 246', '§ 360', '§ 246', '§ 246', '§ 246', '§ 360', '§ 246']

Last Update: 3/5/19
PDF246-887-020
(1) The pharmacy quality assurance commission (commission) adopts Title 21 of the Code of Federal Regulations. The following sections do not apply: Section 1301.13, section 1301.33, section 1301.35-.46, section 1303, section 1308.41-.45, and section 1316.31-.67. Any inconsistencies between Title 21 of the Code of Federal Regulations sections 1300 through 1321 and chapter 246-887 WAC should be resolved in favor of chapter 246-887 WAC. Further, nothing in these rules applies to the production, processing, distribution, or possession of marijuana as authorized and regulated by the Washington state liquor and cannabis board.
(2) Registration. A separate registration is required for each place of business, as defined in 21 C.F.R. 1301.12 where controlled substances are manufactured, distributed or dispensed. Application for registration must be made on forms supplied by the commission, and all requested information must be supplied unless the information is not applicable, which must be indicated by the applicant. An applicant for registration must hold the appropriate wholesaler, manufacturer or pharmacy license provided for in chapter 18.64 RCW.
(3) Every registrant shall be required to keep inventory records required by 21 C.F.R. 1304.04 and must maintain said inventory records for a period of two years from the date of inventory. Such registrants are further required to keep a record of receipt and distribution of controlled substances. Such record shall include:
(c) In the event of a significant loss or theft, two copies of DEA 106 (report of theft or loss of controlled substances) must be transmitted to the federal authorities and a copy must be sent to the commission;
(d) For transfers of controlled substances from one dispenser to another, a record of the transfer must be made at the time of transfer indicating the drug, quantity, date of transfer, who it was transferred to and from whom. Said record must be retained by both the transferee and the transferor. These transfers can only be made in emergencies pursuant to 21 C.F.R. 1307.11.
(4) The records must be maintained separately for Schedule II drugs. The records for Schedule III, IV and V drugs may be maintained either separately or in a form that is readily retrievable from the business records of the registrant.
(6) Schedule II drugs require that a dispenser have a signed prescription in his possession prior to dispensing said drugs. An exception is permitted in an "emergency." An emergency exists when the immediate administration of the drug is necessary for proper treatment and no alternative treatment is available, and further, it is not possible for the physician to provide a written or electronic prescription for the drug at that time. If a Schedule II drug is dispensed in an emergency, the practitioner must deliver a signed prescription to the dispenser within seven days after authorizing an emergency oral prescription or if delivered by mail it must be postmarked within the seven-day period, and further the pharmacist must note on the prescription that it was filled on an emergency basis.
[Statutory Authority: RCW 69.50.201. WSR 19-06-068, § 246-887-020, filed 3/5/19, effective 4/5/19. Statutory Authority: RCW 18.64.005, 2013 c 276, and 2013 c 19. WSR 15-13-086, § 246-887-020, filed 6/15/15, effective 7/16/15. Statutory Authority: RCW 43.70.280. WSR 98-05-060, § 246-887-020, filed 2/13/98, effective 3/16/98. Statutory Authority: RCW 18.64.005. WSR 92-04-029 (Order 239B), § 246-887-020, filed 1/28/92, effective 2/29/92. Statutory Authority: RCW 18.64.005 and chapter 18.64A RCW. WSR 91-18-057 (Order 191B), recodified as § 246-887-020, filed 8/30/91, effective 9/30/91. Statutory Authority: RCW 69.50.201. WSR 89-17-023 (Order 226), § 360-36-010, filed 8/8/89, effective 9/8/89. Statutory Authority: RCW 69.50.301. WSR 87-10-029 (Order 206), § 360-36-010, filed 5/1/87. Statutory Authority: RCW 18.64.005(4). WSR 85-06-010 (Order 193), § 360-36-010, filed 2/22/85. Statutory Authority: RCW 69.50.301. WSR 80-05-074 (Order 154, Resolution No. 4/80), § 360-36-010, filed 4/28/80; WSR 79-10-007 (Order 151, Resolution No. 9/79), § 360-36-010, filed 9/6/79. Statutory Authority: RCW 69.50.301 and chapter 69.50 RCW. WSR 78-02-070 (Order 140), § 360-36-010, filed 1/25/78; Order 132, § 360-36-010, filed 5/4/77; Order 108, § 360-36-010, filed 10/26/71.]
PDF246-887-040
Designation of nonnarcotic stimulant drugs for purposes of RCW 69.50.402 (1)(c).
The pharmacy quality assurance commission hereby designates, the following Schedule II controlled substances as nonnarcotic stimulants for purposes of RCW 69.50.402 (1)(c):
(1) Amphetamine sulfate in any of its generic forms.
(2) Dextroamphetamine sulfate in any of its generic forms and under the following brand names:
(a) Dexedrine (SKF);
(b) Dexedrine spansules (SKF).
(3) Dextroamphetamine HCL in any of its generic forms.
(4) Dextroamphetamine tannate in any of its generic forms.
(5) Methamphetamine HCL (Desoxyephedrine HCL) in any of its generic forms and under the following brand name:
Desoxyn (Abbott).
(6) Amphetamine complex in any of its generic forms and under the following brand names:
(a) Biphetamine 12 1/2 (Pennwalt);
(b) Biphetamine 20 (Pennwalt).
(7) Combined amphetamines sold under the following brand names:
Obetrol-10 and 20 (Obetrol).
(8) Phenmetrazine HCL in any of its generic forms and under the following brand name:
Preludin (Boehringer-Ingelheim).
(9) Methylphenidate HCL in any of its generic forms and under the following brand name:
Ritalin (Ciba).
(10) Lisdexamfetamine in any of its generic forms and under the following brand name:
[Statutory Authority: RCW 18.64.005 and 69.50.402. WSR 16-11-059, § 246-887-040, filed 5/13/16, effective 6/13/16. Statutory Authority: RCW 18.64.005. WSR 92-04-029 (Order 239B), § 246-887-040, filed 1/28/92, effective 2/29/92. Statutory Authority: RCW 18.64.005 and chapter 18.64A RCW. WSR 91-18-057 (Order 191B), recodified as § 246-887-040, filed 8/30/91, effective 9/30/91. Statutory Authority: RCW 69.50.201. WSR 79-08-069 (Order 148, Resolution No. 7-79), § 360-36-115, filed 7/24/79.]
PDF246-887-045
Prescribing, dispensing, or administering of Schedule II nonnarcotic stimulants.
The Schedule II stimulants listed in WAC 246-887-040 may be prescribed, dispensed, or administered to patients for the following disease states or conditions:
(1) Disease states or conditions listed in RCW 69.50.402 (1)(c)(ii);
(2) Multiple sclerosis; and
(3) Moderate to severe binge eating disorder in adults.
[Statutory Authority: RCW 18.64.005 and 69.50.402. WSR 16-11-059, § 246-887-045, filed 5/13/16, effective 6/13/16. Statutory Authority: RCW 69.50.402 and 18.64.005(7). WSR 03-04-045, § 246-887-045, filed 1/28/03, effective 2/28/03.]
PDF246-887-080
Sodium pentobarbital registration disciplinary action.
In addition to any criminal or civil liabilities that may occur, the pharmacy quality assurance commission (commission) may deny, suspend, or revoke registration upon determination that:
(1) The registration was procured through fraud or misrepresentation;
(2) The registrant or any agent or employee of the registrant has violated any of the federal or state laws related to drugs, or has violated any of the rules or regulations of the commission.
[Statutory Authority: RCW 69.50.201. WSR 19-06-068, § 246-887-080, filed 3/5/19, effective 4/5/19. Statutory Authority: RCW 18.64.005 and chapter 18.64A RCW. WSR 91-18-057 (Order 191B), recodified as § 246-887-080, filed 8/30/91, effective 9/30/91. Statutory Authority: RCW 69.50.201. WSR 89-17-023 (Order 226), § 360-36-270, filed 8/8/89, effective 9/8/89; Order 138, § 360-36-270, filed 11/8/77.]
PDF246-887-090
Pursuant to the authority granted to the pharmacy quality assurance commission (commission) in RCW 69.50.201, the commission has considered the following factors with regards to each of the substances listed in this chapter and in chapter 69.50 RCW:
[Statutory Authority: RCW 69.50.201. WSR 19-06-068, § 246-887-090, filed 3/5/19, effective 4/5/19. Statutory Authority: RCW 18.64.005 and chapter 18.64A RCW. WSR 91-18-057 (Order 191B), recodified as § 246-887-090, filed 8/30/91, effective 9/30/91. Statutory Authority: RCW 69.50.201, 69.50.203, 69.50.205, 69.50.207, 69.50.209 and 69.50.211. WSR 84-22-062 (Order 190), § 360-36-400, filed 11/7/84.]
PDF246-887-100
The pharmacy quality assurance commission (commission) finds that the following substances have high potential for abuse and have no accepted medical use in treatment in the United States or that they lack accepted safety for use in treatment under medical supervision. In addition to the substances scheduled in RCW 69.50.204 the commission places each of the following controlled substances by whatever official name, common or usual name, chemical name, or brand name in Schedule I.
(1) Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:
(a) (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); some other names: Acetyl fentanyl;
(2) Opium derivatives. Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: Methylhydromorphine.
(3) Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation. For purposes of this subsection only, the term "isomer" includes the optical, position, and geometric isomers:
(a) Cathinone; also known as 2-amino-1-phenyl-1-propanone, alpha-aminopropiophenone; 2-aminopropiophenone; and norephedrone;
(b) N,N-dimethylamphetamine; some other names: N,N-alpha-trimethyl-benzeneethanamine; and N,N-alpha-trimethylphenethylene.
[Statutory Authority: RCW 69.50.201. WSR 19-06-068, § 246-887-100, filed 3/5/19, effective 4/5/19. Statutory Authority: RCW 18.64.005, 69.50.201, and 69.50.203. WSR 11-22-086, § 246-887-100, filed 11/1/11, effective 12/2/11. WSR 01-03-108, § 246-887-100, filed 1/22/01, effective 1/22/01. Statutory Authority: RCW 18.64.005. WSR 94-08-098, § 246-887-100, filed 4/6/94, effective 5/7/94. Statutory Authority: RCW 18.65.005 and 18.64.005. WSR 94-07-105, § 246-887-100, filed 3/18/94, effective 3/18/94. Statutory Authority: RCW 18.64.005. WSR 92-04-029 (Order 239B), § 246-887-100, filed 1/28/92, effective 2/29/92. Statutory Authority: RCW 18.64.005 and chapter 18.64A RCW. WSR 91-18-057 (Order 191B), recodified as § 246-887-100, filed 8/30/91, effective 9/30/91. Statutory Authority: RCW 69.50.201. WSR 89-17-023 (Order 226), § 360-36-410, filed 8/8/89, effective 9/8/89; WSR 86-16-057 (Order 200), § 360-36-410, filed 8/1/86. Statutory Authority: RCW 69.50.201, 69.50.203, 69.50.205, 69.50.207, 69.50.209 and 69.50.211. WSR 84-22-062 (Order 190), § 360-36-410, filed 11/7/84.]
PDF246-887-140
The pharmacy quality assurance commission (commission) finds that the following substances have a high potential for abuse and have currently accepted medical use in treatment in the United States, or currently accepted medical use with severe restrictions and that the abuse of the following substances may lead to severe psychic or psychological dependence. In addition to the substances listed in RCW 69.50.206, the commission places each of the following drugs and other substances by whatever official name, common or usual name, chemical name, or brand name in Schedule II.
(1) Coca leaves and any salt, compound, derivative, or preparation of coca leaves (including cocaine and ecgonine and their salts, isomers, derivatives and salts of isomers and derivatives), and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions which do not contain cocaine or ecgonine; or [123I]ioflupane.
(2) Opiates. Unless specifically excepted or unless in another schedule any of the following opiates, including its isomers, esters, ethers, salts and salts of isomers, esters and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, dextrorphan and levopropoxyphene excepted: Thiafentanil.
(4) Immediate precursors. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances: Immediate precursor to fentanyl: 4-anilino-N-phenethyl-4-piperidine (ANPP).
[Statutory Authority: RCW 69.50.201. WSR 19-06-068, § 246-887-140, filed 3/5/19, effective 4/5/19. WSR 00-01-075, § 246-887-140, filed 12/13/99. WSR 97-21-054 , § 246-887-140, filed 10/13/97, effective 11/13/97. Statutory Authority: RCW 18.65.005 and 18.64.005. WSR 94-07-105, § 246-887-140, filed 3/18/94, effective 3/18/94. Statutory Authority: RCW 18.64.005. WSR 92-04-029 (Order 239B), § 246-887-140, filed 1/28/92, effective 2/29/92. Statutory Authority: RCW 18.64.005 and chapter 18.64A RCW. WSR 91-18-057 (Order 191B), recodified as § 246-887-140, filed 8/30/91, effective 9/30/91. Statutory Authority: RCW 69.50.201. WSR 89-17-023 (Order 226), § 360-36-420, filed 8/8/89, effective 9/8/89; WSR 86-16-057 (Order 200), § 360-36-420, filed 8/1/86. Statutory Authority: RCW 69.50.201, 69.50.203, 69.50.205, 69.50.207, 69.50.209 and 69.50.211. WSR 84-22-062 (Order 190), § 360-36-420, filed 11/7/84.]
PDF246-887-150
Schedule II immediate precursors.
The pharmacy quality assurance commission (commission) finds and designates the following substances as being the principal compound used or produced primarily for use and which are an immediate chemical intermediary used or likely to be used, in the manufacture of a Schedule II controlled substance, the control of which is necessary to prevent, curtail or limit manufacture.
(1) Unless specifically excepted or listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances or their salts or isomers having potential for abuse associated with the preparation of controlled substances shall be a Schedule II controlled substance.
(2) Any drug or compound containing Ephedrine, or any of its salts or isomers, or Pseudoephedrine, or any of its salts or isomers that are prepared for dispensing or over-the-counter distribution and are in compliance with the Federal Food, Drug and Cosmetic Act and applicable regulations are not controlled substances for the purpose of this section.
[Statutory Authority: RCW 69.50.201. WSR 19-06-068, § 246-887-150, filed 3/5/19, effective 4/5/19. Statutory Authority: RCW 18.65.005 and 18.64.005. WSR 94-07-105, § 246-887-150, filed 3/18/94, effective 3/18/94. Statutory Authority: RCW 18.64.005 and chapter 18.64A RCW. WSR 91-18-057 (Order 191B), recodified as § 246-887-150, filed 8/30/91, effective 9/30/91. Statutory Authority: RCW 18.64.005. WSR 88-11-007 (Order 214), § 360-36-425, filed 5/9/88. Statutory Authority: RCW 18.64.005(11). WSR 88-06-060 (Order 211), § 360-36-425, filed 3/2/88.]
PDF246-887-160
The pharmacy quality assurance commission (commission) finds that the following substances have a potential for abuse less than the substances listed in Schedule I under RCW 69.50.204 and WAC 246-887-100 and Schedule II under RCW 69.50.206 and WAC 246-887-140, and have currently accepted medical use in treatment in the United States and that the abuse of the substances may lead to moderate or low physical dependency or high psychological dependency. In addition to substances listed in RCW 69.50.208, the commission places each of the following drugs and other substances by whatever official name, common or usual name, chemical name, or brand name in Schedule III.
(1) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:
Perampanel, and its salts, isomers, and salt of isomers.
(2) Anabolic steroids. The term "anabolic steroid" means any drug or hormonal substance, chemically and pharmacologically related to testosterone,other than estrogens, progestins, and corticosteroids, that promotes muscle growth, and includes:
(a) 17alpha-methyl-3alpha,17beta-dihydroxy-5alpha-androstane;
(m) Any salt, ester, or isomer of a drug or substance described or listed in this paragraph, if that salt, ester, or isomer promotes muscle growth. Except such term does not include an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the secretary of health and human services for such administration. If any person prescribes, dispenses, or distributes such steroid for human use such person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this subsection.
(3) Exempt anabolic steroid products. The following anabolic steroid products in Table A of this subsection containing compounds, mixtures, or preparations are exempt from the recordkeeping, refill restrictions, and other Controlled Substances Act requirements:
[Statutory Authority: RCW 69.50.201. WSR 19-06-068, § 246-887-160, filed 3/5/19, effective 4/5/19. Statutory Authority: RCW 18.64.005 and 69.50.201. WSR 04-13-162, § 246-887-160, filed 6/23/04, effective 7/24/04. Statutory Authority: RCW 69.50.201 and 18.64.005(7). WSR 03-02-021, § 246-887-160, filed 12/23/02, effective 1/23/03. WSR 00-10-113, § 246-887-160, filed 5/3/00. WSR 00-01-075, § 246-887-160, filed 12/13/99. Statutory Authority: RCW 18.64.005. WSR 96-01-032, § 246-887-160, filed 12/12/95, effective 1/12/96; WSR 94-08-098, § 246-887-160, filed 4/6/94, effective 5/7/94. Statutory Authority: RCW 18.64.005. WSR 93-14-038 (Order 376B), § 246-887-160, filed 6/29/93, effective 7/30/93; WSR 93-06-093 (Order 343B), § 246-887-160, filed 3/3/93, effective 4/3/93; WSR 92-04-029 (Order 239B), § 246-887-160, filed 1/28/92, effective 2/29/92. Statutory Authority: RCW 18.64.005 and chapter 18.64A RCW. WSR 91-18-057 (Order 191B), recodified as § 246-887-160, filed 8/30/91, effective 9/30/91. Statutory Authority: RCW 69.50.201. WSR 89-17-023 (Order 226), § 360-36-430, filed 8/8/89, effective 9/8/89. Statutory Authority: RCW 69.50.201, 69.50.203, 69.50.205, 69.50.207, 69.50.209 and 69.50.211. WSR 84-22-062 (Order 190), § 360-36-430, filed 11/7/84.]
PDF246-887-170
The pharmacy quality assurance commission (commission) finds that the following substances have a low potential for abuse relative to substances in Schedule III under RCW 69.50.208 and WAC 246-887-160, and have currently accepted medical use in treatment in the United States and that the abuse of the substances may lead to limited physical dependence or psychological dependence relative to the substances in Schedule III. In addition to substances listed in RCW 69.50.210, the commission places each of the following drugs and substances by whatever official name, common or usual name, chemical name, or brand name in Schedule IV.
(1) Narcotic drugs. Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set in this subsection: 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol).
(a) Alfaxalone;
(a) Cathine ((+) - norpseudoephedrine);
(b) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
(5) Other substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts: Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its optical isomers) and its salts, isomers, and salts of isomers.
[Statutory Authority: RCW 69.50.201. WSR 19-06-068, § 246-887-170, filed 3/5/19, effective 4/5/19. Statutory Authority: RCW 69.50.201 and 18.64.005. WSR 10-02-080, § 246-887-170, filed 1/5/10, effective 2/5/10. WSR 98-02-084 § 246-887-170, filed 1/7/98, effective 1/7/98. Statutory Authority: RCW 18.64.005. WSR 94-08-098, § 246-887-170, filed 4/6/94, effective 5/7/94; WSR 92-04-029 (Order 239B), § 246-887-170, filed 1/28/92, effective 2/29/92. Statutory Authority: RCW 18.64.005 and chapter 18.64A RCW. WSR 91-18-057 (Order 191B), recodified as § 246-887-170, filed 8/30/91, effective 9/30/91. Statutory Authority: RCW 69.50.201. WSR 89-17-023 (Order 226), § 360-36-440, filed 8/8/89, effective 9/8/89. Statutory Authority: RCW 69.50.201, 69.50.203, 69.50.205, 69.50.207, 69.50.209 and 69.50.211. WSR 84-22-062 (Order 190), § 360-36-440, filed 11/7/84.]
PDF246-887-180
The pharmacy quality assurance commission (commission) finds that the following substances have low potential for abuse relative to substances in Schedule IV under RCW 69.50.210 and WAC 246-887-170 and have currently accepted medical use in treatment in the United States and that the substances have limited physical dependence or psychological dependence liability relative to the substance in Schedule IV. In addition to the substances listed in RCW 69.50.212, the commission places each of the following drugs and substances by whatever official name, common or usual name, chemical name, or brand name in Schedule V.
Depressants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts:
[Statutory Authority: RCW 69.50.201. WSR 19-06-068, § 246-887-180, filed 3/5/19, effective 4/5/19. Statutory Authority: RCW 18.64.005 and chapter 18.64A RCW. WSR 91-18-057 (Order 191B), recodified as § 246-887-180, filed 8/30/91, effective 9/30/91. Statutory Authority: RCW 69.50.201, 69.50.203, 69.50.205, 69.50.207, 69.50.209 and 69.50.211. WSR 84-22-062 (Order 190), § 360-36-450, filed 11/7/84.]
PDF246-887-200
Other controlled substance registrants—Requirements.
(1) All persons and firms, except persons exempt from registration, must register with the pharmacy quality assurance commission (commission) in order to legally possess or use controlled substances.
(2) Persons or firms which are not classified as pharmacies, wholesalers, manufacturers, or researchers will be classified as other controlled substance registrants. Examples of persons or firms in this classification include analytical laboratories, dog handlers/trainers who use dogs for drug detection purposes, school laboratories and other agencies which have a legitimate need to use precursor chemicals as defined in WAC 246-887-150.
(3) The applicant for a controlled substance registration must complete and return an application form supplied by the commission. Either on the form or on an addendum, the applicant must list the controlled substances to be used, the purpose for such use, and the names of the persons authorized to access the controlled substances.
(4) All controlled substances must be stored in a substantially constructed locked cabinet. The registrant shall maintain records in sufficient detail in order to account for the receipt, use, and disposition of all controlled substances. The registrant shall inventory all controlled substances in the possession of the registrant every two years on the anniversary of the issuances of the registration and shall maintain the inventory list for two years. The registrant shall return unwanted, outdated, or unusable controlled substances to the source from which it was obtained or surrendered to the Federal Drug Enforcement Administration.
[Statutory Authority: RCW 69.50.201. WSR 19-06-068, § 246-887-200, filed 3/5/19, effective 4/5/19. Statutory Authority: Chapter 69.50 RCW and RCW 18.64.005. WSR 92-12-035 (Order 277B), § 246-887-200, filed 5/28/92, effective 6/28/92. Statutory Authority: RCW 18.64.005 and chapter 18.64A RCW. WSR 91-18-057 (Order 191B), recodified as § 246-887-200, filed 8/30/91, effective 9/30/91. Statutory Authority: RCW 69.50.201. WSR 89-17-023 (Order 226), § 360-36-500, filed 8/8/89, effective 9/8/89.]
PDF246-887-210
Standards for transmission of controlled substances sample distribution reports.
These standards describe the format for transmission of data regarding distribution of controlled substance samples by manufacturers or distributors to licensed practitioners in the state of Washington.
(1) Each report shall contain the following information regarding the firm distributing controlled substance samples:
(a) Name of firm.
(b) DEA number of firm.
(c) Complete address of firm including zip code.
(d) Name and phone number of contact person.
(2) Each report shall contain the following information regarding the licensed practitioner to whom samples are distributed:
(a) First and last name of practitioner.
(b) DEA number of practitioner.
(c) Professional designation of practitioner. (E.g., MD, DO, DDS.)
(d) Complete address of practitioner including zip code.
(3) Each report shall contain the following information regarding the controlled substance(s) distributed:
(a) Name of controlled substance(s) distributed.
(b) Dosage units of controlled substance(s) distributed.
(c) Quantity distributed.
(d) Date distributed.
(4) Each report shall be submitted in alphabetical order by practitioner's last name.
(5) Each report shall be submitted quarterly.
[Statutory Authority: RCW 18.64.005. WSR 92-09-071 (Order 265B), § 246-887-210, filed 4/14/92, effective 5/15/92.]